Polycystic ovary syndrome (PCOS) is a heterogeneous disorder characterized by hyperandrogenism and chronic anovulation. PCOS is characterized by excessive ovarian and/or adrenal androgen secretion. Intrinsic ovarian factors such as altered steroidogenesis and factors external to the ovary such as hyperinsulinemia contribute to the excessive ovarian androgen production. Characteristic features include more growing follicles in women with PCOS compared with normal controls with premature growth arrest of antral follicles at 5 to 8 mm.
There are several diagnostic guidelines for polycystic ovary syndrome, and though different, each relies on combinations of three major elements to make the diagnosis: ovulatory dysfunction, hyperandrogenism (clinical or biochemical), and ovarian morphology. The National Institutes of Health (NIH) and Androgen Excess Society criteria emphasize the importance of androgen excess in the diagnosis, noting that this identifies a phenotype at greater risk for metabolic complications.
Get FREE sample copy at:
The Polycystic Ovarian Syndrome market report also covers emerging drugs, current treatment practices, Polycystic Ovarian Syndrome market share of the individual therapies, current and forecasted Polycystic Ovarian Syndrome Market Size from 2017 to 2030 segmented by seven major markets.
The report provides a detailed current Polycystic Ovarian Syndrome treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
Polycystic Ovarian Syndrome Market Key Facts
As per the Centers for Disease Control and Prevention, Polycystic Ovarian Syndrome is one of the most common causes of female infertility, affecting 6% to 12% of US women of reproductive age.
As per Office on Women’s Health, between 5% and 10% of women between 15 and 44, or during the childbearing age, have Polycystic Ovarian Syndrome. Most women find out that they have Polycystic Ovarian Syndrome in their 20s and 30s when they have problems getting pregnant and see their doctor. But Polycystic Ovarian Syndrome can happen at any age after puberty.
As per the article by Ding et al., titled “The prevalence of polycystic ovary syndrome in reproductive-aged women of different ethnicity: a systematic review and meta-analysis,” reported that for the 1990 NIH diagnostic criteria, the prevalence of Polycystic Ovarian Syndrome for White women was estimated at 5.5%.
Key Benefits of Polycystic Ovarian Syndrome Market Report
Polycystic Ovarian Syndrome market report provides an in-depth analysis of Polycystic Ovarian Syndrome Market Size, Share, Trend, Epidemiology and Market Forecast till 2030, in 7 major market i.e. EU5 (Germany, Italy, Spain, France and the UK), Japan, and the United States.
The Polycystic Ovarian Syndrome market report will help in developing business strategies by understanding the Polycystic Ovarian Syndrome Market trends & developments, key players and future market competition that will shape and drive the Polycystic Ovarian Syndrome market in the upcoming years.
The Polycystic Ovarian Syndrome market report covers Polycystic Ovarian Syndrome current treatment practices, emerging drugs, market share of the individual therapies in 7 MM.
The report provides a detailed assessment of the Polycystic Ovarian Syndrome market in terms of market drivers & barriers, Unmet Needs, market opportunities, patient population, comparative analysis of pipeline products with detailed clinical profiles, and other factors.
Polycystic Ovarian Syndrome Market
Polycystic Ovarian Syndrome market size is expected to increase during the forecast period owing to the increase in the prevalence of Polycystic Ovarian Syndrome, along with the expected launch of emerging therapies in the 7MM.
The Polycystic Ovarian Syndrome market outlook section of the report helps to build the detailed comprehension of the historic, current and forecasted Polycystic Ovarian Syndrome market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand for better technology.
The report gives a thorough detail of Polycystic Ovarian Syndrome market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders.
Polycystic Ovarian Syndrome Epidemiology
The Polycystic Ovarian Syndrome epidemiology section covers insights about historical and current Polycystic Ovarian Syndrome patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.
It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Polycystic Ovarian Syndrome Drugs Uptake and Key Market Players
The Polycystic Ovarian Syndrome Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Polycystic Ovarian Syndrome market or expected to get launched in the market during the study period. The analysis covers Polycystic Ovarian Syndrome market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Companies across the globe are diligently working toward the development of novel treatment therapies with a considerable amount of success over the years. Key players, such as Zydus Discovery DMCC, Spruce Biosciences, Kindex Pharmaceuticals etc., are developing drugs for the treatment of Primary Polycystic Ovarian Syndrome.
Polycystic Ovarian Syndrome therapies covered in the report include:
And many others.
Table of Content
1. Key Insights
2. Executive Summary
3. Polycystic Ovarian Syndrome Competitive Intelligence Analysis
4. Polycystic Ovarian Syndrome Market Overview at a Glance
5. Polycystic Ovarian Syndrome Disease Background and Overview
6. Polycystic Ovarian Syndrome Patient Journey
7. Polycystic Ovarian Syndrome Epidemiology and Patient Population
8. Polycystic Ovarian Syndrome Treatment Algorithm, Current Treatment, and Medical Practices
9. Polycystic Ovarian Syndrome Unmet Needs
10. Key Endpoints of Polycystic Ovarian Syndrome Treatment
11. Polycystic Ovarian Syndrome Marketed Products
12. Polycystic Ovarian Syndrome Emerging Therapies
13. Polycystic Ovarian Syndrome Seven Major Market Analysis
14. Attribute Analysis
15. Polycystic Ovarian Syndrome Market Outlook (7 major markets)
16. Polycystic Ovarian Syndrome Access and Reimbursement Overview
17. KOL Views on the Polycystic Ovarian Syndrome Market.
18. Polycystic Ovarian Syndrome Market Drivers
19. Polycystic Ovarian Syndrome Market Barriers
21. DelveInsight Capabilities
Polycystic Ovarian Syndrome Epidemiology Forecast
DelveInsight’s Polycystic Ovarian Syndrome – Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Polycystic Ovarian Syndrome in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
Polycystic Ovarian Syndrome Pipeline Analysis
Polycystic Ovarian Syndrome Pipeline Insight, 2020 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Polycystic Ovarian Syndrome market.
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd. 2432
City: Las Vegas
Country: United States